Connect Sign In
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
ARUP’s Clinical Trials and PharmaDx groups supported Blueprint Medicines’ clinical trials that led to FDA approval for AYVAKIT® (avapritinib), a new treatment for indolent systemic mastocytosis.
ARUP and Gestalt Diagnostics announced a partnership under which ARUP will adopt Gestalt’s PathFlow® platform as a foundation for future digital pathology initiatives.
ARUP researchers coauthored more than 160 peer-reviewed articles on groundbreaking research in 2022. Their insights and innovation helped advance laboratory medicine for improved patient outcomes.
The Spring 2023 edition of Magnify: The Art and Science of Diagnostic Medicine, is now available online and explores the legacy and future of transfusion medicine at ARUP.
Joshua M. Zimmerman, MD, can visualize several scenarios in which he could use granular data about a patient’s transfusion risk to better prepare his patients for surgery. With the right information, the medical director of the preoperative clinic at University of Utah Health could intervene weeks…
For 20-plus years, Mark Withers had inexplicable episodes of a severe anaphylaxis-like phenomenon. ARUP’s unique expertise and highly sensitive tests help patients like him find the right diagnosis.
The near total automation installed in ARUP’s Automated Core Lab increases capacity for testing, provides better turnaround times, reduces risk of human error, and improves staff satisfaction.
ARUP’S new test is the first of its kind to use two distinct biomarkers to identify in utero exposure to kratom, an herbal supplement that may cause neonatal abstinence syndrome.
The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
